News & Insights

Gunderson Dettmer represented client Encodia, a biotech company developing next-generation solutions for proteomics research, in its $75 million Series C financing led by Northpond Ventures and Deerfield Management.

Gunderson Dettmer partners Ryan Gunderson and Jeff Thacker hosted a discussion on the benefits and considerations of raising capital from crossover funds as part of a post- IPO Summit series of workshops.

Contineum Therapeutics, a clinical-stage biopharmaceutical company, announces the pricing of an upsized underwritten public offering of 7,346,938 shares of its Class A common stock at a public offering price of $12.25 per share.

Foresite Labs incubated company, Vignette Bio, announces its acquisition by Candid Therapeutics, an innovative biotechnology company developing T-cell engager (“TCE”) antibodies 

Pioneer in the transcatheter treatment of aortic regurgitation (AR), JenaValve Technology, announces its agreement to be acquired by Edwards Lifesciences

The Legal 500 ranked thirteen Gunderson Dettmer partners across multiple offices in its US City Elite 2026 edition, highlighting top legal talent in cities throughout the United States.

Best Lawyers recognizes 38 Gunderson Dettmer attorneys across both the 2026 editions of The Best Lawyers in America list and Best Lawyers: Ones to Watch in America, continuing the legacy of celebrating exceptional legal professionals who have distinguished themselves through insight, expertise, and commitment to excellence

Gunderson Dettmer has been recognized in China Business Law Journal’s 2024 “Deals of the Year” report for our participation in a standout transaction in the PE/VC category.